Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0004968
UniProt IDP04062
Primary gene name(s)GBA
Synonym gene name(s)GC, GLUC
Protein nameGlucosylceramidase
Protein functionunknown
Subcellular locationLysosome membrane {ECO:0000269|PubMed:17187079, ECO:0000269|PubMed:17897319, ECO:0000269|PubMed:18022370};
Peripheral membrane protein {ECO:0000269|PubMed:17187079, ECO:0000269|PubMed:17897319, ECO:0000269|PubMed:18022370};
Lumenal side {ECO:0000269|PubMed:17187079, ECO:0000269|PubMed:17897319, ECO:0000269|PubMed:18022370}. Note=Interaction with saposin-C promotes membrane association. Targeting to lysosomes occurs through an alternative MPR-independent mechanism via SCARB2.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P04062
Gene Ontology
(Biological Process)
Complete annatation
carbohydrate metabolic process [GO:0005975];
cellular response to starvation [GO:0009267];
cellular response to tumor necrosis factor [GO:0071356];
ceramide biosynthetic process [GO:0046513];
glucosylceramide catabolic process [GO:0006680];
glycosphingolipid metabolic process [GO:0006687];
negative regulation of inflammatory response [GO:0050728];
negative regulation of interleukin-6 production [GO:0032715];
negative regulation of MAP kinase activity [GO:0043407];
negative regulation of neuron death [GO:1901215];
negative regulation of protein homooligomerization [GO:0032463];
positive regulation of macroautophagy [GO:0016239];
positive regulation of neuronal action potential [GO:1904457];
positive regulation of protein complex disassembly [GO:0043243];
positive regulation of protein dephosphorylation [GO:0035307];
positive regulation of protein lipidation [GO:1903061];
positive regulation of protein metabolic process [GO:0051247];
positive regulation of proteolysis involved in cellular protein catabolic process [GO:1903052];
regulation of cellular protein metabolic process [GO:0032268];
regulation of lysosomal protein catabolic process [GO:1905165];
regulation of macroautophagy [GO:0016241];
regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032434];
regulation of water loss via skin [GO:0033561];
response to estrogen [GO:0043627];
response to glucocorticoid [GO:0051384];
response to pH [GO:0009268];
response to testosterone [GO:0033574];
response to thyroid hormone [GO:0097066];
skin morphogenesis [GO:0043589];
sphingosine biosynthetic process [GO:0046512];
termination of signal transduction [GO:0023021]
Gene Ontology
(Molecular Function)
Complete annatation
glucosylceramidase activity [GO:0004348];
receptor binding [GO:0005102]
Gene Ontology
(Cellular Component)
Complete annatation
extracellular exosome [GO:0070062];
lysosomal lumen [GO:0043202];
lysosomal membrane [GO:0005765]
Protein-protein interaction108899
Phylogenetic treeP04062
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.4659912256964130.1625083203367750.2592976290616
AZA vs. DISU-0.004386463200883220.9874630054665960.998932793566471
AZA vs. IL7-0.1414432695588730.4677810422177760.999311006273513
AZA vs. SAHA0.05660537946853680.8177095201267360.95403663362155
DISU vs. CD30.4483474876460640.2595309343051980.387151836092682
DISU vs. IL7-0.1470691461935770.618990574810820.88498510197962
DISU vs. SAHA0.06369775322618510.8289442834162370.955499041613743
DMSO vs. AZA-0.008037829485588960.9623270426830921
DMSO vs. CD30.4466843955215360.1689046605278910.261300956136032
DMSO vs. DISU-0.005678630347325710.9834777744954380.997375827320006
DMSO vs. IL7-0.1260911744344550.4887294115990120.884322644198525
DMSO vs. SAHA0.05905512428019460.8035548609282790.945430138492646
HIV vs. Mock in Activation0.1026157555814940.8750942448909490.999983755607037
HIV vs. Mock in Latency0.1240124415968320.458687591644110.999834320637052
IL7 vs. CD30.3304038453983390.3087037688381810.446596785459056
SAHA vs. CD30.4990639817977440.1671212932710610.262591793305691
SAHA vs. IL70.1954459263882810.426618812348620.669106229084436
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.270519 0.044784
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
0.04 0.003

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.051 1.341 1.702 1.789 1.473
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB03106 Myo-Inositol experimental unknown unknown
DB03740 N-acetyl-alpha-D-glucosamine experimental unknown unknown
DB08283 (2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL experimental unknown unknown
DB06720 Velaglucerase alfa approved, investigational unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1OGS X-ray 2.0Å A/B=40-536.
1Y7V X-ray 2.4Å A/B=40-536.
2F61 X-ray 2.5Å A/B=40-536.
2J25 X-ray 2.9Å A/B=40-536.
2NSX X-ray 2.1Å A/B/C/D=40-536.
2NT0 X-ray 1.7Å A/B/C/D=40-536.
2NT1 X-ray 2.3Å A/B/C/D=40-536.
2V3D X-ray 1.9Å A/B=40-536.
2V3E X-ray 2.0Å A/B=40-536.
2V3F X-ray 1.9Å A/B=40-536.
2VT0 X-ray 2.1Å A/B=40-536.
2WCG X-ray 2.3Å A/B=40-536.
2WKL X-ray 2.7Å A/B=40-536.
2XWD X-ray 2.6Å A/B=40-536.
2XWE X-ray 2.3Å A/B=40-536.
3GXD X-ray 2.5Å A/B/C/D=40-536.
3GXF X-ray 2.4Å A/B/C/D=40-536.
3GXI X-ray 1.8Å A/B/C/D=40-536.
3GXM X-ray 2.2Å A/B/C/D=40-536.
3KE0 X-ray 2.7Å A/B=40-536.
3KEH X-ray 2.8Å A/B=40-536.
3RIK X-ray 2.4Å A/B/C/D=40-536.
3RIL X-ray 2.4Å A/B/C/D=40-536.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
HIV-1 virus replication enhanced by expression of human gene 19460752
Tat interacts with 16223608

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00511 Other glycan degradation - Homo sapiens (human)
hsa00600 Sphingolipid metabolism - Homo sapiens (human)
hsa01100 Metabolic pathways - Homo sapiens (human)
hsa04142 Lysosome - Homo sapiens (human)